Scarica l'app Stockscreener
28.61
1.38%
-0.40
Dopo l'orario di chiusura:
28.61
Precedente Chiudi:
$29.01
Aprire:
$28.88
Volume 24 ore:
6,985
Relative Volume:
0.58
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.89%
1M Prestazione:
-6.44%
6M Prestazione:
-13.64%
1 anno Prestazione:
-13.64%
Intervallo 1D:
$28.51
$28.88
Intervallo di 1 settimana:
$28.51
$29.53
Portata 52W:
$28.51
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
Nome
Tema Etf Trust Tema Obesity Cardiometabolic Etf
Settore
Industria
Telefono
-
Indirizzo
-
Confronta HRTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTS
Tema Etf Trust Tema Obesity Cardiometabolic Etf
|
28.61 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
263.96 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
536.70 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
540.07 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
210.85 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
450.66 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Etf Trust Tema Obesity Cardiometabolic Etf Borsa (HRTS) Ultime notizie
Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Declines By 28.6% - Defense World
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Down 60.0% in February - Defense World
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends - ETF Trends
Reshoring ETF Gets Boost From Trump Trade - etf.com
Tema's New VOLT ETF Sparked by AI Revolution - etf.com
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
Tap the Weight-Loss Drug Market With These ETFs - Nasdaq
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Markets Insider
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg.com
Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard
Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
The 5 Best Biotech ETFs of 2024 - etf.com
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Be Thankful — It Could Have Been So Much Worse - Bloomberg
Tema Etf Trust Tema Obesity Cardiometabolic Etf Azioni (HRTS) Dati Finanziari
Non sono disponibili dati finanziari per Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.72%
Capitalizzazione:
|
Volume (24 ore):